Skip to main content

Table 2 Results from drug screening and referenced achievable plasma concentrations

From: A novel canine histiocytic sarcoma cell line: initial characterization and utilization for drug screening studies

Drug

IC50 (μM)

Achievable concentrations in plasma (based on the literature)

BD

DH82

[plasma] (μM)

Species

Dose

Effect

Ref.

Dasatinib

0.01

0.009

0.3

dog

3 mg/kg

NOAEL

[72]

Erlotinib

3.2

4.3

6.9

dog

150 mg

TD

[73]

Gefitinib

30.7

46.4

2.6

dog

100 mg/kg

NOAEL

[74]

Imatinib

34

39.2

0.66

dog

10 mg/kg

NOAEL

[75]

Masitinib

15.7

39.1

1.5

dog

10 mg/kg

TD

[76]

Nilotinib

29.9

26.2

1.4

dog

20 mg/kg

NOAEL

[77]

Toceranib

1.9

1.7

0.1

dog

3.25 mg/kg

TD

[78]

Sorafenib

36.3

13.6

13.3

human

400 mg

TD

[79]

Sunitinib

4.5

17.9

0.12

human

50 mg

TD

[80]

Tozasertib

7.7

1.3

0.27

human

8 mg/m2

TD

[81]

CCNU

105

139.5

4.2

human

130 mg/m2

TD

[69]

Cladribine a

64

222

0.028

human

0.09 mg/kg

TD

[82]

Doxorubicin a

0.09

0.41

1.13

dog

30 mg/m2

TD

[83]

  1. a Compounds administered intravenously
  2. NOAEL: no-observed-adverse-effect level
  3. TD: therapeutic dosage